MedTrace Logo

Prevalence of Antibodies Against SARS-CoV-2 Virus That Causes COVID-19 in Tübingen Children

NCT04581889 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2380

Last updated 2023-11-29

No results posted yet for this study

Summary

This is a prospective, longitudinal study to determine the incidence of SARS-COV-2 infection in children and adolescents by measuring specific antibodies in non-invasive saliva sampled in kindergartens and schools in a defined city area. The study includes an additional arm to validate the ELISA for anti-SARS-COV-2 reactive antibody measurements in saliva compared against blood collected in adult volunteers in a bimonthly follow-up period for 12 months.

Conditions

  • Severe Acute Respiratory Syndrome

Interventions

OTHER

Diagnostic test

Presence of antibodies in saliva

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Andrea Kreidenweiss, Dr. · University Hospital Tübingen

  • Jana Held, Dr · University Hospital Tübingen

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-02
Primary Completion
2021-07-31
Completion
2022-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04581889 on ClinicalTrials.gov